Table 1.
Baseline Characteristics of Subjects With and Without Incident CVD After a Median Follow‐Up of 9.4 Years
| CVD | Non‐CVD | P Value | |
|---|---|---|---|
| n | 182 | 1665 | — |
| Sex, % men | 64.8 | 43.9 | <0.001 |
| Age, y | 62.9±10.9 | 50.9±11.4 | <0.001 |
| Smoking status, % | 42.3 | 24.2 | <0.001 |
| Body mass index, kg/m2 | 25.2±3.54 | 24.0±3.52 | <0.001 |
| Waist circumference, cm | <0.001* | ||
| Men | 87.4±10.2 | 83.8±8.81 | |
| Women | 82.8±8.40 | 75.8±9.02 | |
| Fasting glucose, mmol/L* | 5.56±1.02 | 5.20±0.95 | <0.001 |
| HOMA‐IR** | 2.12 (1.36 to 3.23) | 1.62 (1.14 to 2.41) | <0.001 |
| Diabetes, % | 28.6 | 13.5 | <0.001 |
| Systolic blood pressure, mm Hg* | 134.2±18.9 | 119.2±17.0 | <0.001 |
| Diastolic blood pressure, mm Hg* | 77.3±11.4 | 74.5±10.3 | 0.003 |
| Hypertension, % | 57.7 | 22.5 | <0.001 |
| HDL‐cholesterol, mmol/L* | 1.26±0.35 | 1.41±0.37 | <0.001 |
| LDL‐cholesterol, mmol/L* | 3.40±0.87 | 3.29±0.81 | 0.081 |
| Triglycerides, mmol/L** | 1.30 (0.90 to 1.80) | 1.10 (0.80 to 1.60) | <0.001 |
| Dyslipidemia, % | 77.5 | 62.0 | <0.001 |
| C‐reactive protein, mg/L* | 1.28 (0.63 to 2.42) | 0.68 (0.33 to 1.47) | <0.001 |
| Adiponectin, μg/mL* | 0.881* | ||
| Men | 5.72 (3.84 to 8.54) | 5.51 (3.59 to 8.61) | |
| Women | 6.97 (5.18 to 10.6) | 7.82 (5.36 to 11.5) | |
| A‐FABP, μg/L* | <0.001* | ||
| Men | 22.3 (16.9 to 33.2) | 18.6 (13.7 to 24.7) | |
| Women | 33.9 (25.3 to 44.0) | 23.4 (17.0 to 32.2) | |
Data are expressed as mean±SD or median (interquartile range). CVD indicates cardiovascular disease; HOMA‐IR, homeostasis model assessment–insulin resistance; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; A‐FABP, adipocyte‐fatty acid binding protein.
*
Sex‐adjusted P value.
*
Excluded n=89 subjects on antidiabetic drugs.
*
Excluded n=186 subjects on antihypertensive drugs.
*
Excluded n=44 subjects on lipid‐lowering drugs.
*
Log‐transformed before analysis.